Technical Data
Cathepsin D (CatD, CLN10, CPSD, CTSD, Lysosomal aspartyl peptidase, MGC2311 )
Cathepsin D has been reported to be involved in malignant tumor progression and with prognosis of various human cancers.

Suitable for use in Immunohistochemistry (paraffin-embedded sections). Other applications not tested.

Recommended Dilution:
Immunohistochemistry (paraffin-embedded sections): 1:75-1:200 using ABC method. An incubation period of 30 mins. at RT is suggested.
Optimal dilutions to be determined by the researcher.

Cellular Localization: Cytoplasmic

Positive Control: Breast Carcinoma

Storage and Stability:
May be stored at 4C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot Store at -20C. Aliquots are stable for at least 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
250ul-20CBlue IceHumanRabbit
Not determined
Cathepsin D isolated from human liver
Supplied as a liquid in PBS containing BSA and sodium azide
Recognizes human Cathepsin D. Reacts with the zymogen as well as the activated form of cathepsin D. It stains fibroblasts and macrophages strongly but stains weakly with the myoepithelial cells of breast. It also stains sweat ducts and glands in the skin, islets cells and granules of pancreatic acini.
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Henry JA et al. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer 65:265-71 (1990). 2. Garcia M et al. Immunohistochemical distribution of the 52-kDa protein in mammary tumors: a marker associated with cell proliferation rather than with hormone responsiveness. J Steroid Biochem 27:439-45 (1987)